Skip to content
Open access

The benefit of LDL-C levels below 55 mg/dL in ESKD patients under statin treatment: A target trial emulation study.

Aug 2026 · Atherosclerosis · Vol 421, pp. 121883 · 0 citations · 37 references
Medicine

TL;DR

LDL-C <55 mg/dL was associated with lower cardiovascular mortality in ESKD, supporting further investigation into very low LDL-C targets in this population and supporting further investigation into very low LDL-C targets in this population of patients.

Abstract

Background

AND

Aims

Achieving optimal low-density lipoprotein cholesterol (LDL-C) levels through statin therapy is a cornerstone of cardiovascular disease (CVD) prevention. However, its benefit in end-stage kidney disease (ESKD) remains uncertain, largely because two major randomized controlled trials-4D Study and AURORA Trial-did not demonstrate clear benefits. Notably, the achieved LDL-C levels in these trials remained above current targets for very high-risk populations. We aimed to evaluate whether achieving very low LDL-C levels is associated with improved outcomes in ESKD patients.

Methods

We conducted a sequential analysis within a target trial emulation framework using data from the Chang Gung Research Database. ESKD patients receiving maintenance hemodialysis were identified each November from 2014 through 2018. Eligible patients receiving statin therapy (n = 3431) were categorized into four groups according to LDL-C levels at the index examination: <55 mg/dL (n = 623), 55-74 mg/dL (n = 841), 75-99 mg/dL (n = 913), and ≥100 mg/dL (n = 1054).

Results

In multivariable Cox proportional hazards models, patients with LDL-C <55 mg/dL had a significantly lower risk of cardiovascular death compared with LDL-C ≥100 mg/dL (HR 0.71; 95% [CI], 0.53-0.95). A non-significant trend toward reduced all-cause mortality was also observed in the LDL-C <55 mg/dL group. Restricted cubic spline analyses demonstrated an association between lower LDL-C levels and reduced risks of both all-cause mortality and cardiovascular death.

Conclusions

LDL-C <55 mg/dL was associated with lower cardiovascular mortality in ESKD, supporting further investigation into very low LDL-C targets in this population.

Read PDF

Similar papers

Open access Sep 2026

LDL-C Target Attainment and Treatment Gaps Six Months After Acute Coronary Syndrome: insights from the CALLINICUS-Hellas registry.

BACKGROUND Low-density lipoprotein cholesterol (LDL-C) reduction is the cornerstone of secondary prevention after acute coronary syndrome (ACS). Despite potent lipid-lowering therapies (LLTs), a therapeutic gap persists. We aimed to evaluate LDL-C target attainment according to the 2019 ESC/EAS guidelines, identify pre...

L. Rallidis, D. Tsamoulis, Despoina-Rafailia Benetou et al. · 0 citations
Open access Sep 2026

Predicting LDL-cholesterol reduction variability on statin-ezetimibe therapy: insights from "Jena auf Ziel".

Upfront dual therapy with atorvastatin (80 mg) and ezetimibe (10 mg) achieved robust LDL‑C reduction with low interindividual variability in treatment-naive individuals, which supports current guideline recommendations for immediate combination therapy in very high-risk patients, irrespective of their baseline metaboli...

U. Makhmudova, D. Lütjohann, F. Haertel et al. · 0 citations
Open access Sep 2026

Intensive lipid lowering therapies improve LDL-C goal achievement, but does high Lp(a) remain a barrier?

LDL-C goal achievement is suboptimal in patients undergoing coronary artery bypass grafting (CABG). We aimed to find factors associated with LDL-C goal achievement in patients under stable lipid-lowering therapy (LLT) at admission for CABG. A prospective, observational study was conducted. Stable LLT was d...

H. Abfalterer, Lori Renz, Christopher Klingler et al. · 0 citations
Open access Oct 2026

Early efficacy of oral lipid lowering therapy in achieving LDL-C targets following acute coronary syndrome: A real-world observational study

Low LDL-C target attainment following ACS remains suboptimal despite high-intensity statin therapy, highlighting the need for earlier and more intensive lipid-lowering strategies in high-risk Indian patients.

A. Gautam, Sudesh Prajapathi, Abhishek Singh et al. · 0 citations
Review Open access Aug 2026

Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets

This expert position paper proposes practical algorithms for a precision medicine approach in Latin America, matching treatment intensity to individual risk profiles for the primary and secondary prevention of atherosclerotic cardiovascular disease.

C. Ponte-Negretti, A. Lorenzatti, Fernando S. Wyss-Quintana et al. · 0 citations
Open access Sep 2026

GUIDELINE-DIRECTED LIPID GOAL ATTAINMENT IN PATIENTS WITH DIABETES AT HIGH AND VERY HIGH CARDIOVASCULAR RISK: REAL-WORLD EVIDENCE OF A PROFOUND TREATMENT GAP

Objective: To evaluate lipid-lowering therapy patterns and the attainment of guideline-directed low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) goals among high and very high-risk patients with diabetes mellitus in a real-world clinical setting.Material and Methods:...

Tolga Aydin · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.